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Abstract  
Aim: Prescribing in type 2 diabetes has changed markedly in recent years, with 
increasing use of newer, more expensive glucose-lowering drugs. We aimed to describe 
population-level time trends in both prescribing patterns and short-term patient 
outcomes (HbA1c, weight, blood pressure, hypoglycemia and treatment discontinuation) 
after initiating new therapy. 
Materials and methods: We studied 81,532 UK patients with type 2 diabetes initiating 
a first to fourth line drug in primary care between 2010-2017 inclusive (Clinical Practice 
Research Datalink). Trends in new prescriptions and subsequent six and twelve-month 
adjusted changes in glycemic response (reduction in HbA1c), weight, blood pressure, 
and rates of hypoglycemia and treatment discontinuation were examined.  
Results: DPP4-inhibitor use second-line near doubled (41% of new prescriptions in 
2017 vs. 22% 2010), replacing sulfonylureas as the most common second-line drug 
(29% 2017 vs. 53% 2010). SGLT2-inhibitors, introduced in 2013, comprised 17% of 
new first-fourth line prescriptions by 2017. First-line use of metformin remained stable 
(91% of new prescriptions in 2017 vs. 91% 2010). Over the study period there was little 
change in average glycemic response and treatment discontinuation. There was a 
modest reduction in weight second and third-line (second line 2017 vs. 2010: -1.5 kg 
(95%CI -1.9;-1.1), p<0.001), and a slight reduction in systolic blood pressure first to 
third-line (2017 vs. 2010 difference range -1.7 to -2.1 mmHg, all p<0.001). 
Hypoglycemia rates decreased second-line (incidence rate ratio 0.94 per-year (95%CI 
0.88;1.00, p=0.04)), mirroring the decline in use of sulfonylureas. 
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Conclusions: Recent changes in prescribing of therapy in type 2 diabetes have not led 
to a change in glycemic response and have resulted in modest improvements in other 
population-level short-term patient outcomes.  
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Introduction 
 
Prescribing of glucose-lowering therapies for patients with type 2 diabetes has changed 
markedly in recent years. International guidelines have been updated to include a much 
greater choice of agents when additional therapies after metformin are required to 
achieve glycemic control.(1-4) Newer drug classes including DPP4-inhibitors, SGLT2-
inhibitors and GLP-1 receptor agonists are now established alongside the longstanding 
options sulfonylureas, thiazolidinediones and insulin. Choice between these agents is 
left largely to the clinician and patient. Recent studies show that there have been 
marked changes in which agents are initiated after metformin, with a declining use of 
sulfonylureas and increasing and earlier use of DPP4-inhibitors and SGLT2-inhibitors in 
both the US, Europe and UK.(5-8)  
 
Although studies have suggested the glucose-lowering effectiveness of agents typically 
added to metformin may be comparable,(1, 9, 10) there are well established differences 
between the different drug classes in weight change and side-effects. GLP-1 receptor 
agonists and SGLT2-inhibitors are associated with weight loss whereas DPP4-inhibitors 
are weight neutral and sulfonylureas can promote weight gain.(9, 10) Hypoglycemia risk 
is greater with sulfonylureas and insulin relative to other agents.(9) Despite these known 
differences in non-glycemic effects between agents, evidence of the impact of recent 
changes in prescribing on population-level patient outcomes is limited.(5, 7, 11, 12) In 
this study we aimed to describe changes in prescribing of glucose-lowering drugs for 
patients initiating first to fourth line therapy between 2010 and 2017 in the UK, a setting 
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where prescribing does not reflect the ability of patients to pay. We further examined 
population-level time trends in the short-term clinical outcomes of glycemic response, 
weight change, blood pressure change, hypoglycemia, and treatment discontinuation. 
 
Materials and methods 
 
Data source and data extraction 
We conducted a population-based analysis of anonymized primary care data from the 
UK’s Clinical Practice Research Database (CPRD). CPRD is a population 
representative database containing demographic, clinical and prescription primary care 
records of patients.(13) Although CPRD includes full prescription records no data on 
drug dispensation are available. CPRD has been extensively used to study drug 
prescribing and patient outcomes in type 2 diabetes.(14) We analyzed data from the 
January 2018 release of CPRD, including all practices that were still contributing to 
CPRD in 2017 to ensure that changes in prescribing did not reflect changes in the 
practices captured in CPRD over the study period. We classified glucose-lowering drugs 
into drug classes according the British National Formulary sections 6.1.1 and 6.1.2.(15) 
Drugs were categorised as metformin, sulfonylureas, thiazolidinediones, DPP4-
inhibitors, GLP-1 receptor agonists, SGLT2-inhibitors, insulin or Other (Meglitinides and 
alpha-glucosidase inhibitors, which are prescribed very rarely in the UK). Scientific 
approval was granted by the CPRD Independent Scientific Advisory Committee (ISAC 
13_177RA4R). 
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Study population 
We extracted the clinical and prescription records of all patients with type 2 diabetes 
who started at least one glucose-lowering drug for the first time ever between 1st 
January 2010 and 31st December 2017 and met CPRD quality assurance criteria 
(n=78,857). Inclusion criteria and data ascertainment followed our previously reported 
CPRD cohort profile.(16) Type 2 diabetes was defined largely on the basis of 
prescriptions for non-insulin diabetes therapies rather than diagnostic medical codes to 
minimize coding errors.(17) We excluded patients with diagnostic codes for other forms 
of diabetes or polycystic ovary syndrome which can be treated with metformin. To 
remove patients with type 1 diabetes, who may be miscoded as Type 2, we excluded 
patients with an age at diagnosis <35 or on insulin treatment within 12 months of 
diagnosis. Consequently, patients with type 2 diabetes whose first-line therapy was 
insulin were not included. We defined date of diabetes diagnosis as the earliest of: first 
prescription for a non-insulin diabetes therapy; first HbA1c result >=6.5% (48 
mmol/mol); or first diabetes diagnostic code. 
 
Study design  
The study exposure was a new first to fourth line drug prescription record for a patient 
within the study period. New drug prescriptions (and their corresponding start dates) 
were defined as the first ever prescription of a drug in a class for a patient. First, 
second, third or fourth-line prescription categories were defined based on the order of 
new drug prescriptions for individual patients. Every time a patient started a new drug 
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class we assigned this to the next line of therapy, regardless of whether their 
concomitant therapy changed at a similar time point.  
  
The primary unit of analysis was line of therapy. This meant individual patients who 
started more than one new therapy over the study period contributed to the analysis 
more than once at different lines of therapy (see Supplementary Flowchart).  
 
Study outcomes 
For each line of therapy, we evaluated annual time trends in the drug classes initiated, 
and time trends in changes in HbA1c, weight, systolic and diastolic blood pressure, 
hypoglycemia rates and treatment discontinuation after therapy start. To evaluate all 
outcomes we used a ‘new user’ design which mitigated immortal time bias.(18) Patients 
were followed up from their drug start date until there was any change in diabetes 
therapy or the end of the study period specific to each outcome. A change in therapy 
could be the addition of a new glucose-lowering drug or the stopping of the drug of 
interest or any concomitant glucose-lowering drug. Patients were considered to have 
stopped a drug if there was a subsequent gap in prescribing of that drug for at least 6 
months.(16) 
 
We defined glycemic response (the change in HbA1c), weight change and blood 
pressure change as the absolute change from baseline to 6 months (6 month measure 
minus baseline measure). For glycemic response, baseline HbA1c was defined as the 
closest HbA1c to the drug start date in the 3 months prior to the drug start date. HbA1c 
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at 6 months was defined as the closest HbA1c to 6 months after the drug start date (+/-
3 months). Glycemic response was only valid if there were no changes in glucose-
lowering therapy between 2 months prior to the baseline HbA1c and the date of the 6 
month HbA1c. The same approach was used for weight change and blood pressure 
change.  
 
We defined hypoglycemia as the first Read code for hypoglycemia up to 2 years after 
starting a line of therapy, using a previously published Read code list for 
hypoglycemia.(19) Due to the low number of hypoglycemia events captured in primary 
care we grouped data into biannual categories representing four distinct periods (2010-
11, 2012-13, 2014-15, 2016-17).  
 
We examined treatment discontinuation by estimating the proportion of patients who 
stopped a therapy within 3 months, 6 months and 1 year. 6 months follow-up after 
discontinuation was required to determine no new prescriptions were issued. 
 
Statistical analysis 
We examined annual time trends for each clinical outcome and each line of therapy in 
separate analysis. We described trends in baseline clinical characteristics as mean 
(standard deviation) per calendar year. All outcomes analyses were standardized to the 
mean baseline values of relevant measures for patients starting that line of therapy in 
2017. 
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To evaluate changes in relative prescribing for each line of therapy we calculated the 
proportion of new prescriptions for each drug class in each calendar year as the: 
                                             
                                 
 
When describing first-line therapy all drugs except metformin and sulfonylureas were 
pooled. Within drug class trends for DPP4 inhibitors, GLP-1 receptor agonists, SGLT2-
inhibitors and sulfonylureas (2014-2017) were estimated using the same approach.  
 
We evaluated non-linear time trends in glycemic response, weight change and blood 
pressure change for each calendar year using linear regression with calendar year as a 
categorical covariate and adjustment for baseline HbA1c, age at therapy, duration of 
diabetes, and the baseline measure of the outcome for non-glycemic outcomes. We 
used complete case analysis including patients only if they had both a valid baseline 
measure and a valid 6 month measure. To assess the potential influence of missing 
data we compared the characteristics of the patients with missing data with those 
included in the analysis. Multiple imputation was not conducted as it is only valid under 
the missing at random assumption (meaning the differences between the observed and 
missing data could can be explained by other recorded measures), and we felt missing 
outcome data were likely to depend on their actual value (missing not at random). 
Hypoglycemia biannual time trends were estimated as rates per 1,000 person-years 
using Poisson regression, adjusted for age, duration, and baseline HbA1c.  
 
Summary measures for each outcome (including baseline HbA1c) were calculated as 
follows; 1) the 2017 vs. 2010 marginal contrast from the multivariable linear regression 
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rti
cl
e
models described above;(20) 2) the linear time trend, as the beta coefficient from a 
multivariable linear regression treating calendar year as a continuous rather than 
categorical covariate.  
 
To evaluate changes in treatment discontinuation we calculated the proportion of new 
prescriptions that were stopped within 3 months, 6 months and 1 year for each line of 
therapy for each calendar year as: 
                                                            
                                 
 
All data extraction and analysis was conducted in Stata v14.0. 
 
Sensitivity analysis 
We repeated all outcomes analysis using change in each measure from baseline to 12 
months as the outcome in a distinct cohort of patients with 12 month measures of each 
outcome (closest +/-3 months as for the definition of 6 month change). Participants 
commencing therapy in 2017 were not included in this analysis as 12 months of patient 
follow-up had not accrued. We also evaluated the sensitivity of results to our definition 
of line of therapy by repeating all second-line analyses in a subset of patients who were 
initiated on metformin first-line and then added a different therapy to metformin (rather 
than stopping metformin). To assess whether changes in outcomes over time were 
likely to be due to changes in the drugs prescribed we compared time trends in weight 
change and hypoglycaemia using the same models described above, with drug as an 
additional covariate. 
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Results 
123,990 new first to fourth line prescriptions from 81,532 individual patients were 
eligible for inclusion. 40% (50,215) were for a first-line prescription, 26% (32,071) were 
second-line, 20% (25,024) were third-line and 13% (16,680) were fourth-line 
(Supplementary Flowchart). The baseline clinical characteristics of patients starting 
each line of therapy in 2017 are shown in Supplementary Table 1. Average baseline 
HbA1c increased second to fourth-line over the study period; average baseline weight 
increased first-line but there was little difference for other lines of therapy. The 
proportion of patients with valid data for analysis of each outcome is shown in the 
Supplementary Flowchart. 
 
Changing prescribing of glucose lowering therapy  
We found marked changes in relative prescribing of second to fourth-line therapy 
(Figure 1). DPP4-inhibitors were by 2017 the most commonly initiated second-line 
therapy (2017 41% of new second-line; 2010 22% of new second-line), whilst second-
line prescribing of sulfonylureas decreased (2017 29%; 2010 53%). SGLT2-inhibitors 
were the most common fourth-line therapy in 2017 (40% prescriptions) and their use 
second-line (19% of new 2017 prescriptions) and third-line (28% of new 2017 
prescriptions) increased rapidly following their introduction in 2013. Fourth-line 
prescribing of injectable therapy decreased (GLP-1 receptor agonists: 2017 11%, 2010 
20%; insulin: 2017 17%, 2010 21%), and remained low second and third-line. First-line 
use of metformin remained stable (2017 91%; 2010 91%).   
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Evaluating new first to fourth line drug initiations as a whole (Supplementary Figure 1), 
we found SGLT2-inhibitors (17% of total new prescriptions in 2017) were more 
commonly initiated in 2017 than sulfonylureas (14% in 2017). New prescribing of insulin 
(2017 5%; 2010 5%) and GLP-1 receptor agonists (range 4% to 3%) remained constant 
over the study period. 
 
Changes in within class prescribing 
In addition to changes in class of agent there have been marked recent changes in 
prescription of individual agents within a class. Over 2014 to 2017 for DPP4-inhibitors, 
there was decreasing use of sitagliptin (2017 37%; 2014 56%), but increasing use of 
alogliptin (2017 25%; 2014 1%) and linagliptin (2017 31%; 2014 25%) (Supplementary 
Figure 2a). For GLP-1 receptor agonists use of once-weekly dulaglutide increased to 
51% of the class total following its introduction in 2015. For SGLT-2 inhibitors there was 
increasing use of empagliflozin (2017 46%; 2015 8%) but decreasing use of 
dapagliflozin (2017 41%; 2014 92%) (Supplementary Figure 2c). Gliclazide use has 
remained stable (2017 91% of all sulfonylureas; 2010 89%) (Supplementary Figure 2d).  
 
Reduction in HbA1c 
Average reductions in HbA1c at 6 months were relatively constant over 2010 to 2017 
across all lines of therapy (Figure 2). There was no evidence of a change in glycemic 
response for second-line therapy (2017 vs. 2010 change 0.0% (-0.1 mmol/mol), 
p=0.80). For first, third, and fourth-line therapy there was evidence of a statistically 
significant trend towards improved glycemic response, although this translated to a 
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modest absolute improvement in reduction in HbA1c (2017 vs. 2010 change range 0.2-
0.3% (1.3 to 2.5 mmol/mol), all p<0.05).  
 
Weight change 
Although there was a trend towards greater weight loss at 6 months for all lines of 
therapy, this was most marked second and third-line (2017 vs. 2010 second-line -1.5kg 
and third-line -1.2kg, both p<0.001; overall time trends for improvement in weight 
change p<0.001 for all lines of therapy) (Figure 3). Patients starting second-line therapy 
on average lost rather than gained weight when comparing 2017 with 2010.  
 
Blood pressure 
We found a trend towards a modest improvement in systolic blood pressure at 6 months 
for all lines of therapy (2017 vs. 2010 range -1.7 to -2.1 mmHg, all p<0.001, 
Supplementary Figure 3a). There was no change in diastolic blood pressure 
(Supplementary Figure 3b). 
 
Hypoglycemia 
We observed a decrease in hypoglycemia rates for patients starting second-line therapy 
(2017 rate 5.7 (95% CI 3.5; 7.9) per 1,000 person-years; 2010 rate 8.2 (95% CI 6.3; 
10.1) per 1,000 person-years (Figure 4, Supplementary Table 2).  
 
Treatment discontinuation 
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Treatment discontinuation at 3 months, 6 months and 1 year after initiating therapy was 
stable over 2010-2017 (Supplementary Table 3). The proportion of patients 
discontinuing within 3 months in 2017 compared to 2010 was as follows: first-line 4% vs 
3%; second-line 7% vs 9%; third-line 12% vs 9%; fourth-line 10% vs 9%.  
 
Sensitivity analysis  
Baseline characteristics of patients excluded as they did not have valid clinical 
measures were similar to those included in analysis (Supplementary Table 4). Time 
trends for outcomes at 12 months were similar to at 6 months for glycemic response 
(Supplementary Figure 4), weight change (Supplementary Figure 5), and blood 
pressure (Supplementary Figure 6). Second-line prescribing trends and patient 
outcomes in the subset of patients adding a second-line drug to continued first-line 
metformin therapy (73% of patients included in the primary analysis) were near identical 
to the primary analysis (Supplementary Figure 7). Differences in weight change trends 
became minimal when models were adjusted for drug therapy as a covariate 
(Supplementary Table 5a), and after adjustment for drug there was no evidence of a 
difference in risk of hypoglycemia over time (Supplementary Table 5b). 
 
Discussion 
Our study describes, for the first time, recent population-level time trends in patient 
outcomes after initiating glucose-lowering therapy over 2010 to 2017, a period where 
there was drastic changes in type 2 diabetes prescribing patterns. There were modest 
population-level improvements in weight change and rates of hypoglycemia for patients 
starting additional therapy after metformin, but little change in glycemic response, blood 
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pressure change or treatment discontinuation. Data on these important short-term 
clinical outcomes provide timely context to the worldwide trend towards prescribing of 
newer more costly glucose-lowering agents. We also provide updated information on 
UK prescribing trends: 1) increased and earlier initiation of DPP4-inhibitors; 2) reduced 
initiation of sulfonylureas second-line; 3) a rapid increase in initiation of SGLT2-
inhibitors; and 4) decreased initiation of injectable therapy (GLP-1 receptor agonists and 
insulin). 
 
Whilst our retrospective analysis precludes causal inference and can only show 
temporal correlation, the time trends in patient outcomes reflect the known effects of the 
different drug classes on clinical outcomes. As might be expected from previous 
comparative analysis,(9, 10) there was an improvement in weight change and reduction 
in rates of hypoglycemia where there was a rapid increase in the use of SGLT2-
inhibitors and DPP4 inhibitors in place of sulfonylureas. These changes were attenuated 
by adjustment for drug, supporting the suggestion that the population-level 
improvements relate to changes in prescribing. Although recent meta-analyses have 
found little difference in glycemic response when comparing therapies added to 
metformin,(1, 9) some studies have reported increased response with sulfonylureas 
compared with other agents,(21-23) or lower response with DPP4-inhibitors,(10) and so 
it is reassuring that we found second-line glycemic response was stable despite the shift 
in prescribing. Newer agents, in particular SGLT2-inhibitors, have been associated with 
modestly lower blood pressure.(24-27) However whilst there were small improvements 
over time in blood pressure change with second to fourth-line therapy there were also 
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improvements first-line where prescribing was unaltered. This suggests that 
improvements do not solely reflect prescribing changes. 
 
The trends in new prescribing in this study are consistent with previous studies of UK 
primary care data,(7) including a recent analysis which documented extensive 
geographical variation in UK prescribing.(6) Comparison with US data suggest newer 
therapies have been adopted more quickly in the UK than in the US; in the US 
sulfonylureas remain the most common second-line therapy.(5) However, trends in new 
prescribing are similar in the US, with decreasing second-line use of sulfonylureas (46% 
of new second-line prescribing in 2016 compared to 55% in 2010) and increasing use of 
DPP4-inhibitors (20% in 2016; 14% in 2010). The increased cost of newer agents may 
explain their relatively slower uptake in the US.(5) 
 
There are limited recent studies in time trends of patient outcomes. A recent analysis of 
1.7 million US Medicare patients found no overall change in glycemic control or rates of 
hypoglycemia over 2006 to 2013, but unlike our study did not study patients initiating 
new therapy.(12) Declining overall rates of hypoglycemia requiring hospitalization were 
observed in UK patients over, but not under, 65 from 2009 to 2013 in the context of 
declining use of sulfonylureas in this older age group.(28) The changes observed in 
these studies examining the overall population of patients with type 2 diabetes will lag 
considerably behind those observed in our analysis of new therapy initiation, as once 
initiated a glucose lowering therapy may be continued for decades.  
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Strengths of the study include our approach examining new prescribing, which allowed 
interrogation of time trends whilst accounting for the increasing prevalence of type 2 
diabetes, which in the UK is due more recently to declining mortality rather than 
increasing incidence,(29, 30) and means prescribing of glucose-lowering therapy is 
increasing in absolute terms.(6, 31) Our definition of type 2 diabetes should minimize 
misclassification.(16) Our study provides a near complete picture of UK prescribing, as 
in the UK type 2 diabetes is largely managed in primary care. Even new therapy 
initiated on the advice of a specialist will usually be prescribed by the patients’ primary 
care physician. A limitation of this study is the weakness in the way hypoglycemia is 
recorded. It is likely that many episodes of hypoglycemia will be missing from a patients’ 
primary care record, as mild hypoglycemia or more severe hypoglycemia requiring 
attendance in secondary care are poorly recorded. However, previous studies have 
provided useful insight into hypoglycemia using similar definitions in the same 
dataset.(32) Although the missing records mean the absolute rates of hypoglycemia in 
this study will be an underestimate, the specificity of our key finding, a relative decrease 
in hypoglycemia rates second-line where use of sulfonylureas has markedly declined, is 
reassuring. Whilst our study provides timely information on population-level trends, 
further observational studies, building on recent work, will be needed to establish the 
real-world comparative effectiveness of individual drug classes at different lines of 
therapy.(10, 33) 
  
Our results show that prescribing of glucose lowering therapy in Type 2 diabetes is 
rapidly changing towards newer, more expensive agents. Changes in prescribing 
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appear to have pre-empted rather than reflected changes to clinical guidelines.(1) In 
particular second-line prescribing of DPP4-inhibitors increased rapidly long before 
treatment guidelines were updated to position them along sulfonylureas and 
pioglitazone as second-line options.(1)  The positive trends in weight change, 
hypoglycemia and blood pressure are likely to have improved the quality of life for 
patients, and a reduction in hypoglycemia is also likely to have a cost benefit.(34)  
However, given the much higher cost of newer drug options, the modest improvement 
we observed in patient outcomes suggests further studies are needed to evaluate cost-
effectiveness of the newer glucose-lowering agents. Recent evidence suggests there 
may be potential for a more stratified approach to prescribing of type 2 diabetes 
therapy, meaning prescribing decisions can be better informed through identification of 
patients or subgroups who differ in their likely glycemic response or risk of side-effects 
with individual agents.(2, 35, 36)  
 
We did not evaluate microvascular or macrovascular outcomes in this study, but a 
cardiovascular benefit in select participants with established cardiovascular disease or 
at high risk, has recently been demonstrated in individual trials for the SGLT2-inhibitors 
empagliflozin and canagliflozin, and GLP-1 receptor agonist liraglutide.(24, 37, 38) A 
recent meta-analysis of randomized trials suggested that in contrast to SGLT2-inhibitors 
and GLP-1 receptor agonists there is no short term mortality benefit with DPP4-
inhibitors.(39) Given the recent changes in treatment guidelines to consider 
cardiovascular risk when choosing therapy,(4) and the fact all three classes have now 
been prescribed in significant numbers for some years, an evaluation of longer-term 
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rti
cl
e
trends in microvascular and macrovascular complications would be of considerable 
interest. 
 
Conclusions 
The trend towards prescribing of newer, more expensive, glucose-lowering medication 
in the UK has coincided, for patients initiating new therapy, with a likely reduction in 
hypoglycemia rates and a modest improvement in weight and blood pressure, but little 
change in glycaemic response or treatment discontinuation. These results demonstrate 
the potential population-level impact of the rapid changes which are occurring in 
prescribing of glucose-lowering therapy worldwide.  
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Figure Legends 
 
 
Figure 1: Time trends in new drug prescriptions for a) first-line b) second-line c) third-line 
d) fourth-line therapy. The prescriptions for each drug class each year are given as a 
percentage of total new drug prescriptions for that year.   
 
Figure 2: Mean HbA1c response at 6 months, 2010-2017 for a) first-line b) second-line c) 
third-line d) fourth-line. Error bars are 95% confidence intervals. Data are standardised to the 
average baseline HbA1c, age at diagnosis and duration of diabetes, specific to each drug line in 
2017. 
 
Figure 3: Mean change in weight at 6 months, 2010-2017 for a) first-line b) second-line c) 
third-line d) fourth-line. Error bars are 95% confidence intervals. Data are standardized to the 
average baseline weight, baseline HbA1c, age at diagnosis and duration of diabetes, specific to 
each drug line in 2017. 
 
Figure 4: Hypoglycaemia rates per 1,000 person-years by 2 year period for a) first-line b) 
second-line c) third-line d) fourth-line therapy. Rates represent the occurrence of 
hypoglycaemia over the first two years after starting a line of therapy. 
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